WO2003009858A1 - Fermentation medium and method - Google Patents
Fermentation medium and method Download PDFInfo
- Publication number
- WO2003009858A1 WO2003009858A1 PCT/US2002/023264 US0223264W WO03009858A1 WO 2003009858 A1 WO2003009858 A1 WO 2003009858A1 US 0223264 W US0223264 W US 0223264W WO 03009858 A1 WO03009858 A1 WO 03009858A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- acid
- yeast
- fermentation medium
- ions
- comprised
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/14—Fungi; Culture media therefor
- C12N1/16—Yeasts; Culture media therefor
- C12N1/18—Baker's yeast; Brewer's yeast
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
Definitions
- yeast tends to be a good host cell to produce many recombinant proteins, to obtain high yields of the polypeptide, it has been necessary to add yeast cell extract to the fermentation medium.
- yeast extract is expensive.
- Prior art efforts to produce a fermentation medium that does not contain yeast cell extract have been disappointing because the resultant yields of the recombinant protein are drastically reduced.
- Figure 1 graphically shows a comparison of the yields of rh factor XTJI expressed in S. cerevisiae using various fermentation media.
- the present invention fills this need by providing for a defined yeast fermentation medium recipe that does not contain yeast cell extract and is comprised of organic acids, preferably oleic acid, lactic acid and palmitic acid.
- the yields of recombinant (r) human (h) factor XIII obtained using S. cerevisiae grown in rich medium containing 3% yeast extract range were 1750 mg/L with a dry cell weight of 72.5 g/L.
- the yields of factor XIII in the same recipe minus the yeast extract were 546 mg/L with a dry cell weight of 62.5 g/L.
- the addition of 10 g/L glutamic acid improved the actor XHI yields to 754 mg/L and the dry cell weight (DCW) to 73.4 g/L.
- the factor XIH yields were less than 50%.
- a number of additives such as additional amino acids were tried, but the yields were not improved.
- compounds such as Tween 80 (poly sorbate mono oleate) and ergosterol are added to improve growth.
- a mixture of organic acids comprised of oleic acid, lactic acid and palmitic acid was added to the minimal medium (#7 of table 1) along with lOg/L glutamic acid to improve rh factor XHI yields.
- the yield of factor XQI improved 250% by the addition of the organic acid mix comprised of oleic acid, lactic acid and palmitic acid.
- the present invention also encompasses a method for producing a heterologous protein from yeast comprising growing a yeast containing DNA that expresses a heterologous protein in the fermentation medium of the present invention.
- This method outlines a new fermentation processes for the production of factor XIII by Saccharomyces cerevisiae transfected with a vector encoding rh factor XTJI.
- the process is a glucose fed batch fermentation utilizing a completely defined fermentation medium.
- the medium is supplemented with glutamic acid to increase growth over the basic defined recipe. It was found that the addition of 0.5 g/L of an organic acid mix containing oleic acid, lactic acid and palmitic acid at a ration of 6:3: 1 in 100% EtOH, increased factor XIII yields by 250%.
- the yields in the defined medium are higher than obtained with the same basic recipe containing 30 g/L yeast extract.
- baffled shake flasks were prepared with 100 ml of seed medium # 9 ( see table 1). Autoclave flasks, and after cooling aseptically add the glucose and vitamin solutions. To each flask 0.4 ml of seed medium contain S. cerevisiae transfected with a vector contain a polynucleotide encoding rh factor XTJI were added. The flasks were incubated with shaking at 30°C, 250 rpm.
- the fermentation methods were developed using New Brunswick Scientific' s BioFlo 3000 fermentation systems.
- the BioFlo 3000 fermentors have the usual temperature and pH control as well as DO (dissolved oxygen) control.
- the DO control cascade utilizes an initial increase in agitation speed (350-950 rpm), followed by an increase in aeration (aeration left constant at lvvm / starting volume), and followed by oxygen sparging (not normally required).
- the vessels have a 6.6 L maximum capacity, but the fermentations usually only reach the 5.0 liter level.
- the vessels are initially prepared with 3.0 liters of media. This has required the upper impeller to be lowered just below the 3.0 liter level. While this may have some negative effects on oxygen transfer, unwanted foaming is eliminated.
- Fermentation vessels were prepared with 3.0 liters of recipe # 7 or # 8 (see table 1). The vessels were sterilized for 45 minutes at 121°C in an autoclave. The vessels were allowed to cool and equilibrate overnight at 30°C.
- the pH controller was set to pH 5.0. Only NF jOH [5 N] is used. No acid is required.
- the fermenter was inoculated with 250 ml of a 24 hour shake flask culture.
- the OD 600 should be between 6 to 8 OD units.
- EFT elapsed fermentation time
- Vitamin solution inoculum, seed, and main fermentor
- biotin 0.160 g thiamine hydrochloride 2.56 g pyrodoxine HC1 2.56 g inositol 48.0 g calcium pantothenate 48.0 g niacinamide 1.92 g folic acid 0.32 g riboflavin 0.64 g choline chloride 3.20 g
- Fermentation F13-120 was grown in a defined medium plus 3% yeast extract.
- F13-135 was grown in a completely defined medium containing 10 g/L glutamic acid and 0.5 g/L organic acid mix. Both were supplied glucose at the same feed rate. While the fermentation in complex medium obtained 1700 mg/L, the fermentation on defined medium reached 1925 mg/L. This is an improvement without the need for yeast extract.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Botany (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003515250A JP2005503784A (en) | 2001-07-23 | 2002-07-23 | Fermentation medium and method |
CA002455722A CA2455722A1 (en) | 2001-07-23 | 2002-07-23 | Fermentation medium and method |
IL15985602A IL159856A0 (en) | 2001-07-23 | 2002-07-23 | Fermentation medium and method |
EP02750240A EP1416947A4 (en) | 2001-07-23 | 2002-07-23 | Fermentation medium and method |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30730201P | 2001-07-23 | 2001-07-23 | |
US60/307,302 | 2001-07-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003009858A1 true WO2003009858A1 (en) | 2003-02-06 |
Family
ID=23189128
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/023264 WO2003009858A1 (en) | 2001-07-23 | 2002-07-23 | Fermentation medium and method |
Country Status (6)
Country | Link |
---|---|
US (1) | US6750045B2 (en) |
EP (1) | EP1416947A4 (en) |
JP (1) | JP2005503784A (en) |
CA (1) | CA2455722A1 (en) |
IL (1) | IL159856A0 (en) |
WO (1) | WO2003009858A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105985428A (en) * | 2015-02-10 | 2016-10-05 | 许健 | Procoagulant function of human recombinant blood coagulation factor XIII |
WO2017092841A1 (en) * | 2015-12-03 | 2017-06-08 | Merck Patent Gmbh | Chemically defined media for the growth or detection of microorganisms |
US10501769B2 (en) | 2009-10-26 | 2019-12-10 | Hoffmann-La Roche Inc. | Method for the production of a glycosylated immunoglobulin |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3958089B2 (en) * | 2002-03-26 | 2007-08-15 | 有限会社新世紀発酵研究所 | Continuous culture of anaerobic bacteria |
KR100797152B1 (en) | 2006-11-24 | 2008-01-23 | 고려대학교 산학협력단 | Method for scale-up production of saccharomyces serevisiae jul3 comprising abundant beta;-glucan |
US9012190B2 (en) | 2011-06-15 | 2015-04-21 | Butamax Advanced Biofuels Llc | Use of thiamine and nicotine adenine dinucleotide for butanol production |
JP6429627B2 (en) | 2012-08-24 | 2018-11-28 | 国立大学法人山口大学 | Yeast medium |
CN111733198B (en) * | 2020-07-24 | 2024-03-26 | 开封康诺药业有限公司 | Fermentation method for improving coenzyme I yield |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5612456A (en) * | 1988-11-14 | 1997-03-18 | Zymogenetics, Inc. | Factor XIII compositions |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5849559A (en) * | 1994-08-26 | 1998-12-15 | Gist-Brocades, B.V. | Arabinoxylan degrading enzymes |
EP0797670A1 (en) * | 1995-10-13 | 1997-10-01 | Gist-Brocades B.V. | Fungal cellulases |
-
2002
- 2002-07-23 US US10/201,168 patent/US6750045B2/en not_active Expired - Fee Related
- 2002-07-23 WO PCT/US2002/023264 patent/WO2003009858A1/en active Application Filing
- 2002-07-23 CA CA002455722A patent/CA2455722A1/en not_active Abandoned
- 2002-07-23 JP JP2003515250A patent/JP2005503784A/en active Pending
- 2002-07-23 EP EP02750240A patent/EP1416947A4/en not_active Withdrawn
- 2002-07-23 IL IL15985602A patent/IL159856A0/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5612456A (en) * | 1988-11-14 | 1997-03-18 | Zymogenetics, Inc. | Factor XIII compositions |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10501769B2 (en) | 2009-10-26 | 2019-12-10 | Hoffmann-La Roche Inc. | Method for the production of a glycosylated immunoglobulin |
US11021728B2 (en) | 2009-10-26 | 2021-06-01 | Hoffmann-La Roche Inc. | Method for the production of a glycosylated immunoglobulin |
US11136610B2 (en) | 2009-10-26 | 2021-10-05 | Hoffmann-La Roche Inc. | Method for the production of a glycosylated immunoglobulin |
US11377678B2 (en) | 2009-10-26 | 2022-07-05 | Hoffman-La Roche Inc. | Method for the production of a glycosylated immunoglobulin |
CN105985428A (en) * | 2015-02-10 | 2016-10-05 | 许健 | Procoagulant function of human recombinant blood coagulation factor XIII |
WO2017092841A1 (en) * | 2015-12-03 | 2017-06-08 | Merck Patent Gmbh | Chemically defined media for the growth or detection of microorganisms |
Also Published As
Publication number | Publication date |
---|---|
EP1416947A4 (en) | 2005-07-20 |
JP2005503784A (en) | 2005-02-10 |
CA2455722A1 (en) | 2003-02-06 |
US20030059925A1 (en) | 2003-03-27 |
EP1416947A1 (en) | 2004-05-12 |
IL159856A0 (en) | 2004-06-20 |
US6750045B2 (en) | 2004-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0156355B2 (en) | Method of improving the yield of heterologous protein produced by cultivating recombinant bacteria | |
EP0436625A1 (en) | Mixed feed recombinant yeast fermentation | |
US6750045B2 (en) | Fermentation medium and method | |
US5334512A (en) | Fatty acid supplemented medium for recombinant production of human serum albumin by yeast | |
EP0656419B1 (en) | Method for highly purifying human serum albumin | |
JP2977241B2 (en) | Optimized fermentation method for exogenous protein production in Escherichia coli | |
EP1994138B1 (en) | Process for preparing human g-csf | |
AU2002319639A1 (en) | Fermentation medium and method | |
EP0736605B2 (en) | Process for producing proteins | |
CA2136564C (en) | Process for producing human serum albumin | |
EP1996697A2 (en) | Preventing norvaline and norleucine misincorporation in recombinant proteins | |
CN111909859B (en) | Low-temperature culture medium for pichia pastoris | |
JPH03500969A (en) | fermentation method | |
CN118006716B (en) | Method for preparing recombinant human albumin with high expression and low O-glycosylation level | |
CN118166053A (en) | Method for preparing recombinant human albumin with low O-glycosylation level | |
CN116286939B (en) | Method for improving nucleic acid yield of saccharomyces cerevisiae and application | |
Chu et al. | Fermentation process optimization of recombinant Saccharomyces cerevisiae for the production of human interferon-α2a | |
CN101139583A (en) | Recombinant human growth hormone (rhGH) highly effective expression method | |
JP3772355B2 (en) | Method for producing human serum albumin | |
AU8715891A (en) | Method of improving the yield of heterologous proteins produced by streptomyces lividans | |
US20060286631A1 (en) | Method for preparating t-20 peptide by high cell density cultivation of recombinant e. coli containing t-20 peptide coding gene | |
KR810000047B1 (en) | Process for preparation of citric acid by fed batch culture | |
JP2818277B2 (en) | Method for producing palmitoleic acid | |
CN101153269A (en) | High-efficiency representation method of regrouped human growth hormone | |
KR970006156B1 (en) | A process for culturing of recombinated yeast containing a dna of presurface antigen and surface antigen in hepatitis type b virus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG UZ VN YU ZA ZM Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 159856 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 111/CHENP/2004 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003515250 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2455722 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002750240 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002319639 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2002750240 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |